CSL-VIFOR
25.11.2022 07:01:37 CET | Business Wire | Press release
Regulatory News:
Tomorrow is Iron Deficiency Day. For the eighth consecutive year, CSL Vifor is supporting a growing alliance of international organizations including the Heart Failure Policy Network, European Kidney Health Alliance, Global Heart Hub and Croí the West of Ireland Cardiac Foundation to advocate people at risk to listen to their body, to take iron seriously and to take control over their health by seeking early diagnosis and medical help from their physician.
“We are pleased to join our patients, healthcare professionals and partners in supporting Iron Deficiency Day 2022, a call for people around the world to get informed and to understand what can happen when iron levels are not properly managed,” said Hervé Gisserot, General Manager of CSL Vifor. “We are dedicated to building awareness of iron deficiency and iron deficiency anemia, to help patients understand their symptoms, improve access and ultimately receive appropriate treatment.”
Iron deficiency and iron deficiency anemia affect one in every two chronic heart failure patients 2,3 and is associated with reduced quality of life4, reduced exercise capacity and increased risk of hospitalization5. Despite the serious consequences and high prevalence of iron deficiency, the condition remains under-recognized6.
The importance of iron for the health of heart failure patients was recently highlighted in the new whitepaper “Heart Failure, an inconvenient truth” which advocates for an extension of current heart failure management strategies to include and increasingly focus on improving quality of life. This includes early diagnosis and treatment of iron deficiency.
“Iron deficiency is a highly prevalent and serious condition among heart failure patients and has a significant impact on their quality of life,”, said Steven Macari, President of AVEC France and co-author of Heart Failure, an inconvenient truth. “It is easily diagnosed and treatable, yet many primary care professionals often overlook symptoms of iron deficiency like fatigue and breathlessness as expected comorbidities of heart failure, and it is often the proactive empowered patient who informs and suggests to be tested. It is therefore vital that we inform practitioners around the importance of diagnosing and treating iron deficiency in patients at risk, and that patient organizations inform their members.”
To learn more about the importance of early diagnosis and recognizing symptoms of iron deficiency, visit www.takeironseriously.com/check-your-symptoms. Use hashtags #TakeIronSeriously and #IDDay2022 on Twitter and LinkedIn.
Iron Deficiency Day is endorsed by multiple international organizations in the United Kingdom, Ireland, Romania, Greece, Saudi Arabia, Russia and for the first time in Slovakia.
About “Heart Failure, an inconvenient truth”
The whitepaper “Heart Failure, an inconvenient truth” is based on a pan-European survey among more than 600 heart failure patients and has been developed together with Pumping Marvellous (UK), AVEC (FR), Herzschwäche Deutschland (DE), The Patients Voice (NL), and Vintura. The aim of the paper, which was funded by CSL Vifor, is to advocate for a better quality of life in heart failure. It can be downloaded here: (https://www.viforpharma.com/sites/vifor-corp/files/White%20paper%20_heart%20failure_V10.2_Digital.pdf)
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
Notes to Editors
Takeironseriously.com is intended to provide educational information to an international audience outside the US; it is available in 14 languages. All information on the site is intended for educational purposes only and should not be used to replace a discussion with a healthcare professional. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.
About iron deficiency
Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide7, yet despite the serious consequences and high prevalence8, it remains an under-recognized condition.
Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five9. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being10. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality10. Common symptoms include fatigue10, 12, 13 pale skin12, brittle nails12, 14, craving non-food items such as dirt, clay and ice15, and an inability to concentrate10, 16. In children, iron deficiency can significantly impair cognitive and motor development17.
The World Health Organization has published new guidelines to help the detection of iron deficiency and iron overload. These guidelines provide global, evidence-informed recommendations on the use of indicators for assessing iron status and application of the use of ferritin concentrations, an indicator of iron storage. Find more here: https://www.who.int/publications/i/item/9789240000124
References
- Hassan, Tamer Hasan et al. “Impact of Iron Deficiency Anemia on the Function of the Immune System in Children.” Ed. Esaki M. Shankar. Medicine 95.47 (2016): e5395. PMC. Web. 12 June 2018.
- Ebner N, von Haehling S. Iron deficiency in heart failure: a practical guide. Nutrients. 2013;5(9):3730-9. doi:10.3390/nu5093730.
- Klip IT, Comin-Colet J, Voors A a, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J. 2013;165(4):575-582.e3. doi:10.1016/j.ahj.2013.01.017.
- Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
- Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
- Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
- Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
- World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.
- Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).
- Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
- Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.
- Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
- Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.
- Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.
- Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
- Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.
- World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esentia Announces Successful Pricing of 6.125% Senior Notes Due 2033 and 6.500% Senior Notes Due 20388.5.2026 03:24:00 CEST | Press release
Esentia Energy Development, S.A.B. de C.V. (“ESENTIA” or the “Company”), today announced the pricing of U.S.$1,000,000,000.00 aggregate principal amount of its 6.125% Senior Notes due 2033 (the “2033 Notes”) and U.S$1,000,000,000.00 aggregate principal amount of its 6.500% Senior Notes due 2038 (the “2038 Notes” and, together with the 2033 Notes, the “Notes”) to be issued by the Company in a private offering to qualified institutional buyers in accordance with Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in accordance with Regulation S under the Securities Act. The 2033 Notes will be issued at a price of 99.517%, and the 2038 Notes will be issued at a price of 98.444%. The 2033 Notes mature on July 30, 2033, and the 2038 Notes mature on July 30, 2038, and will be fully and unconditionally guaranteed by certain of the Company's subsidiaries. The settlement of the Notes is expected to take place on May 14
83% of Restaurants Are Invisible in AI Search: New Uberall Report Reveals the Discovery Gap Reshaping the Quick Service Restaurant Industry7.5.2026 19:35:00 CEST | Press release
Industry-first benchmark study analyzes how ChatGPT, Gemini, Perplexity, Copilot and Google AI Overviews recommend restaurants Uberall, the global leader in location marketing technology, today released Fast Food, Faster Discovery: The 2026 GEO Playbook for Multi-Location QSRs — the industry’s first benchmark report measuring how AI assistants recommend restaurants and how multi-location QSR (Quick-Service Restaurant) brands can adapt their local marketing strategies for AI-mediated search. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507962493/en/ Fast Food, Faster Discovery: Why AI Is the New Drive-Thru The report draws on Uberall’s proprietary GEO Studio benchmark data and aggregated performance metrics from its global QSR customer base. Its central finding: as consumer restaurant discovery rapidly shifts from traditional search to AI assistants, the majority of QSR locations are effectively absent from AI-generated
Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi7.5.2026 18:57:00 CEST | Press release
Initially focused on women’s health, the partnership will unite Department of Health - Abu Dhabi’s longitudinal health data with ŌURA’s real-time insights, underpinned by a rigorous joint data governance framework Department of Health—Abu Dhabi (DoH) and ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a joint research programme to study how continuous wearable data can advance preventive health. The collaboration marks the beginning of a long-term partnership to advance Abu Dhabi’s prevention-first, data-driven healthcare agenda, and will initially focus on women’s health and cardiometabolic risk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507073495/en/ HE Mansoor Al Mansoori (Left) and Tom Hale (Right) The collaboration builds on Abu Dhabi’s advanced public health infrastructure and longitudinal health data assets, integrating them with ŌURA’s real-time, continuous insights across key health
Rave Sues Apple in Five Countries Over App Store Removal7.5.2026 17:03:00 CEST | Press release
Alleges Antitrust Violations in U.S., Canada, Brazil, the Netherlands and Russia to Restore Access for Users and Defend Fair Competition for App DevelopersAlleges Apple Acted to Stop Rave from Competing with Apple’s Own Co-Viewing AppRave Launches Proprietary, AI-enabled Moderation System, a-eye.com, to Protect Users from Explicit Content Rave Inc. (“Rave” or the “Company”), the developer and operator of the Rave app, a cross-platform co-viewing “super app” with more than 225 million downloads, today announced that it has filed antitrust lawsuits against Apple in five countries: the United States, Canada, Brazil, the Netherlands and Russia. The lawsuits challenge Apple’s unilateral and anticompetitive decision to remove Rave from its App Store, thereby distorting competition, reducing consumer choice in co-viewing functionalities and increasing the costs to users of switching between iPhone and competing smartphone devices. Rave operates a social entertainment app that allows users in
emnify named a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide7.5.2026 17:00:00 CEST | Press release
First-time positioned vendor emnify recognized for its Completeness of Vision and Ability to Execute emnify, a global provider of cloud-native IoT connectivity solutions, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507642325/en/ emnify named a Visionary in the 2026 Gartner® Magic Quadrant™ for Managed IoT Connectivity Services, Worldwide. Get the report As a first-time recognized vendor, emnify believes this recognition reflects its forward-looking approach to IoT connectivity, building a platform designed to anticipate where enterprise needs are heading rather than replicating the connectivity models of the past. "We feel being named a Visionary in our first appearance in the Gartner® Magic Quadrant™ recognizes our deliberate strategy of the last decade: from owning our core netw
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
